Atopic Dermatitis News and Research

RSS

Atopic dermatitis is a long-term skin disease. "Atopic" refers to a tendency to develop allergy conditions. "Dermatitis" means swelling of the skin. Atopic dermatitis is most common in babies and children. But it can happen to anyone. People who live in cities and dry climates may be more likely to get this disease. When children with atopic dermatitis grow older, this problem can improve or go away. But the skin may stay dry and easy to irritate. At other times, atopic dermatitis is a problem in adulthood. You can't "catch" the disease or give it to other people.

Skin infections in AD patients linked to PMN impairment

Impairment of polymorphonuclear granulocytes among patients with atopic dermatitis may represent an additional cause of skin infections, suggest study findings.

22 Jun 2012

Stiefel to acquire WBI-1001 licensing rights from Welichem

Stiefel, a GSK company, and Welichem Biotech Inc., have entered into an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories in the world outside of China, Taiwan, Macao and Hong Kong.

31 May 2012

Intensity of itching in eczema linked to depression

Itch intensity in atopic dermatitis is related to the stress level and emotional wellbeing of patients, say researchers.

30 May 2012

PTH boosts AMPs to fend off infection-causing microbes

Antimicrobial peptides (AMPs) are molecules produced in the skin to fend off infection-causing microbes. Vitamin D has been credited with a role in their production and in the body's overall immune response, but scientists at the University of California, San Diego School of Medicine say a hormone previously associated only with maintaining calcium homeostasis and bone health is also critical, boosting AMP expression when dietary vitamin D levels are inadequate.

24 May 2012

Provectus announces final data from PV-10 Phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

9 May 2012

Clinical data from Anacor’s tavaborole and AN2728 study to be presented at upcoming meetings

Anacor Pharmaceuticals announced today that it will be presenting clinical data on its lead compounds, tavaborole and AN2728, at the following upcoming medical meetings.

5 May 2012

Mount Sinai experts to share skin cancer prevention tips on May 7

Skin cancer is the most common form of cancer in the United States, with one in five Americans developing it over the course of their lives. It's also one of the most preventable types of cancers. Since May is Skin Cancer Awareness Month and Melanoma Monday is May 7, Mount Sinai experts are sharing tips on prevention and insight on the new FDA labeling requirements on sunscreen.

30 Apr 2012

Provectus announces data from PV-10 Phase 2 study on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 study of PV-10 for metastatic melanoma will be presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012.

10 Apr 2012

NEA Itching for a Cure 5K Walk to take place on April 28

The National Eczema Association (NEA) is proud to announce the FIRST ever walk for eczema: Itching for a Cure. The NEA Itching for a Cure 5K Walk will take place Saturday, April 28, 2012, in Asheville, North Carolina, on the University of North Carolina-Asheville campus.

6 Apr 2012

Meda opens China affiliate based in Beijing

Meda has established an affiliate in Hong Kong. At the end of last year, Meda opened its China affiliate based in Beijing. Meda will begin by commercializing two of its well-established products in Hong Kong; Elidel for the treatment of atopic dermatitis (eczema) and azelastine for the treatment of allergic rhinitis.

3 Apr 2012

Top-line data from Provectus' PH-10 Phase 2 trial on plaque psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced top-line data for the company's randomized controlled trial (RCT) of PH-10 for mild-to-moderate plaque psoriasis.

19 Mar 2012

KYTHERA commences two ATX-101 Phase III trials for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, today announced the initiation of two pivotal U.S. Phase III trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental (under the chin) fat.

5 Mar 2012

Creabilis initiates CT327 Phase IIb trial in psoriasis vulgaris

Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, today announced the start of the Phase IIb global clinical trial of its lead product CT327 in patients with psoriasis vulgaris. Recruitment is progressing well.

29 Feb 2012

Study identifies new processes that lead to development of novel cell implicated in allergies

A collaboration between scientists in Trinity College Dublin and the United Kingdom has identified new processes that lead to the development of a novel cell implicated in allergies. The discovery has the potential for new strategies to treat asthma and other allergic diseases.

28 Feb 2012

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.

13 Feb 2012

GSK voluntarily pauses enrollment in GSK2251052 clinical trials for cUTI

Anacor Pharmaceuticals announced today that its partner GlaxoSmithKline has voluntarily paused enrollment in its current clinical trials of GSK2251052 due to a recently identified microbiological finding in a small number of patients in the Phase 2b trial of GSK '052 for the treatment of complicated urinary tract infections (cUTI).

6 Feb 2012

Enrollment complete in two Anacor's tavaborole Phase 3 trials on onychomycosis

Anacor Pharmaceuticals announced today that it has completed the enrollment of approximately 600 patients in the second of its two Phase 3 trials of tavaborole, a topical anti-fungal product candidate for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

23 Dec 2011

Provectus presents data from PV-10 Phase 2 study at 2011 International Melanoma Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida.

14 Nov 2011

Provectus announces data from Phase 2 PV-10 metastatic melanoma study

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting.

11 Nov 2011

Enrollment complete in Anacor's first of two tavaborole Phase 3 trials for onychomycosis

Anacor Pharmaceuticals announced today that it has completed enrollment in the first of two Phase 3 trials of tavaborole (formerly known as AN2690), a topical anti-fungal product candidate for the treatment of onychomycosis.

9 Nov 2011